Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand? - Test2 - elhamkhani - TriplyDB

Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?

Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?

http://www.wikidata.org/entity/Q55246604

about

Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?

http://www.wikidata.org/entity/Q55246604

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?

@en

Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?

@nl

type

label

Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?

@en

Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?

@nl

prefLabel

Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?

@en

Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?

@nl

P1433

Q55246604-804555CC-393B-46F7-B29F-A8F2F178CB42

P1476

Q55246604-4E0A6E65-6931-4D09-BEF3-7A996DB593ED

P2093

Q55246604-0297D129-1533-404D-9A2F-A383FE74D105

Q55246604-D2FD5EF8-800A-496C-BFE9-1100BBA2B8EF

P2860

Q55246604-0720605F-2B3B-4EB1-8831-C60F7FA0B4A3

Q55246604-0777A71F-6038-492B-BE79-E5C75C9FE971

Q55246604-07C868B9-E743-48E2-88B3-7AD04D24A331

Q55246604-0BA53493-100E-4E7D-8237-8260857AF459

Q55246604-17EC4893-6A4B-466B-8E8D-E4641E0B8D7C

Q55246604-1A8C7C8F-7537-458F-9A97-3E721A4A8F48

Q55246604-23321651-2481-422D-AD32-A8712EC078BD

Q55246604-27D1A393-30DF-4438-B1BD-577D29A39FBC

Q55246604-2F74F5F6-0A1A-4628-B4BD-D5AEAD63DA95

Q55246604-34CE6A6B-7C93-4FA3-9D13-A49FBC302619

P304

Q55246604-B678BB37-7751-4C27-B146-8460900966EE

P31

Q55246604-68836774-0FD6-4C69-850F-66E01DC2A79E

P356

Q55246604-D4ECEC77-2252-42C9-A2D0-0BEA478C7510

P478

Q55246604-9AB99CA8-BA3C-44FF-BD50-01091ED69484

P577

Q55246604-8F7BD26D-868E-4B75-9306-950783C4A48C

P698

Q55246604-94AB519E-B5B9-4EBF-95B2-7F7D129B0422

P932

Q55246604-118DD275-59B9-4BC1-A7D2-DC9839D92FB9

P356

J.CTRO.2017.10.005

P1433

Clinical and Translational Radiation Oncology

P1476

Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?

@en

P2093

Haitham Mirghani

http://www.w3.org/2001/XMLSchema#string

Pierre Blanchard

http://www.w3.org/2001/XMLSchema#string

P2860

Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma

Human papillomavirus and survival of patients with oropharyngeal cancer.

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or ..

Comprehensive genomic characterization of head and neck squamous cell carcinomas

A review of human carcinogens--Part B: biological agents

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship.

P304

4-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CTRO.2017.10.005

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29594236

http://www.w3.org/2001/XMLSchema#string

P932

5862680

http://www.w3.org/2001/XMLSchema#string